同步放化疗对晚期宫颈癌患者肿瘤标志物及血清TK1、HE4、VEGF的影晌

目的：分析研究同步放化疗对晚期宫颈癌患者肿瘤标志物及血清胸苷激酶1（TKl）、人附睾分泌蛋白4（HE4）、血管内皮生长因子（VEGF）的影响。方法：选取本院收治的78例晚期宫颈癌患者为研究对象，将其随机分为对照组（常规放疗组）39例和观察组（同步放化疗组）39例，然后将两组治疗有效率及治疗前后的血清肿瘤标志物及血清TKl、HE4、VEGF水平进行比较。结果：观察组的治疗有效率明显高于对照组，治疗后1个周期及3个周期时的血清肿瘤标志物及血清TKl、HE4、VEGF水平均明显低于对照组，差异具有统计学意义（P〈0．05）。结论：同步放化疗在晚期宫颈癌患者中的应用效果较好，且对于肿瘤标志物及血清TKl、HE4、VEGF也有一定影响，因此更适用于此类患者。

Influence of concurrent chemoradiotherapy on tumor markers and serum TK1,HE4, VEGF in patients with advanced cervical cancer

Objective.. To analyze and study the influence of concurrent chemoradiotherapy for the tumor markers and serum TK1, HE4,VEGF in patients with advanced cervical cancer. Methods. A total of 78 patients with advanced cervical cancer were selected as research object,and they were randomly divided into control group（routine radiotherapy group, n=39 cases）and observation group（concurrent cbemora diotherapy group, n=39 cases） ,then the treatment effective rates and serum tumor markers,TK1, HE4, VEGF levels before and at＇ter the treatment of two groups were analyzed and compared. Results：The treat ment effective rates of observation group were obviously higher than those of control group,serum tumormarkers, TK1, HE4, VEGF at 1 cycle and 3 cycles after the treatment were all obviously lower than those of control group （P0.05）. Oonclusion..The effect of concurrent chemoradiotherapy in patients with ad- vanced cervical cancer is better, and its influence for the tumor markers and serum TK1, HE4, VEGF of pa- tients is more active too, so it is more suitable for these patients .